PLA2G5, phospholipase A2 group V, 5322

N. diseases: 29; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1856718
Disease: Fleck Retina, Familial Benign
Fleck Retina, Familial Benign 		0.700 GermlineCausalMutation disease ORPHANET Biallelic mutations in PLA2G5, encoding group V phospholipase A2, cause benign fleck retina. 22137173 2011
CUI: C1856718
Disease: Fleck Retina, Familial Benign
Fleck Retina, Familial Benign 		0.700 GeneticVariation disease UNIPROT Biallelic mutations in PLA2G5, encoding group V phospholipase A2, cause benign fleck retina. 22137173 2011
CUI: C1856718
Disease: Fleck Retina, Familial Benign
Fleck Retina, Familial Benign 		0.700 GeneticVariation disease CLINVAR
CUI: C1856718
Disease: Fleck Retina, Familial Benign
Fleck Retina, Familial Benign 		0.700 Biomarker disease CTD_human
CUI: C1856718
Disease: Fleck Retina, Familial Benign
Fleck Retina, Familial Benign 		0.700 Biomarker disease GENOMICS_ENGLAND
CUI: C0015397
Disease: Disorder of eye
Disorder of eye 		0.300 Biomarker group GENOMICS_ENGLAND
CUI: C0015397
Disease: Disorder of eye
Disorder of eye 		0.300 Biomarker group GENOMICS_ENGLAND
CUI: C0015397
Disease: Disorder of eye
Disorder of eye 		0.300 Biomarker group GENOMICS_ENGLAND
CUI: C0201657
Disease: C-reactive protein measurement
C-reactive protein measurement 		0.100 GeneticVariation phenotype GWASCAT Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease. 31070471 2019
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 GeneticVariation disease GWASCAT Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia. 27903959 2017
CUI: C0202117
Disease: Low density lipoprotein cholesterol measurement
Low density lipoprotein cholesterol measurement 		0.100 GeneticVariation phenotype GWASDB Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. 23063622 2012
CUI: C0202236
Disease: Triglycerides measurement
Triglycerides measurement 		0.100 GeneticVariation phenotype GWASDB Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. 23063622 2012
CUI: C0428474
Disease: Serum LDL cholesterol measurement
Serum LDL cholesterol measurement 		0.100 GeneticVariation phenotype GWASDB Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. 23063622 2012
CUI: C1445957
Disease: Serum total cholesterol measurement
Serum total cholesterol measurement 		0.100 GeneticVariation phenotype GWASDB Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. 23063622 2012
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 GeneticVariation group BEFREE In addition, we found a correlation between <i>PLA2G5</i> gene expression and both epithelial-mesenchymal transition and the isocitrate dehydrogenase 1 mutation status in these tumors. 31114356 2019
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.020 GeneticVariation disease BEFREE Our results demonstrate the association of the PLA2G5 rs11573191 polymorphism with premature CAD. 24959594 2014
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.020 AlteredExpression disease BEFREE Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. 24563418 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 Biomarker group BEFREE The candidate genes located at amplified regions of chromosomes or low-level gain regions such as PLA2G5 (1p36-p34), COL11A1 (1p21), KCNK2 (1q41), S100A3 (1q21), ENAH (1q42.12), RGS1 (1q31), KCNH1 (1q32-q41), INSIG2 (2q14.1), FGF12 (3q28), TRIO (5p15.2), RNASEN (5p15.2), FGF10 (5p13-p12), EDN1(6p24.1-p22.3), SULF1 (8q13.2-13.3), TLR4 (9q32-q33), TNC (9q33), NTRK2 (9q22.1), CD44 (11p13), NCAM1 (11q23.1), TRIM29 (11q22-q23), PAK1 (11q13-q14) and RAB27A (15q15-q21.1), are found to be associated with cellular migration and proliferation, tumor cell metastasis and invasion, anchorage independent growth and inhibition of apoptosis. 20083228 2010
CUI: C3714514
Disease: Infection
Infection 		0.020 Biomarker group LHGDN Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells. 16146426 2006
CUI: C3714514
Disease: Infection
Infection 		0.020 AlteredExpression group LHGDN Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease. 15377291 2004
CUI: C0017638
Disease: Glioma
Glioma 		0.010 AlteredExpression disease BEFREE The immunohistochemistry of the 82 glioma tissues further confirmed that PLA2G5 protein expression was dependent on the WHO glioma grade. 31114356 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.010 AlteredExpression phenotype BEFREE A calcium-dependent phospholipase A2 (cPLA2) expression is regulated by MIG-6 during endometrial tumorigenesis. 30773264 2019
CUI: C0014457
Disease: Eosinophilia
Eosinophilia 		0.010 Biomarker disease BEFREE Unexpectedly, while adoptive transfer of bone marrow-derived (BM)-macrophages restored ILC2 activation and eosinophilia in Alternaria-exposed Pla2g5-null mice, exogenous IL-33 did not. 29346348 2018
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.010 Biomarker disease BEFREE Group V phospholipase A<sub>2</sub> (Pla2g5) is a lipid-generating enzyme necessary for macrophage effector functions in pulmonary inflammation. 29346348 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.010 GeneticVariation disease BEFREE An association between the BanI polymorphism of the PLA2G4A gene for calcium-dependent phospholipase A2 and plasma glucose levels among females with schizophrenia. 30103930 2018